• In early August 2026, Twist Bioscience completed a US$300 million follow-on common stock offering at US$96 per share after raising its fiscal 2026 revenue guidance to US$456 million–US$457 million and reporting third-quarter sales of US$118.38 million despite a net loss of US$35.05 million.

• Alongside this capital raise and upgraded outlook, Twist is addressing legacy securities litigation through a proposed US$17.05 million class-action settlement process that could help clear a legal overhang for shareholders.

• Next, we'll examine how Twist's upgraded revenue guidance and capital raise reshape its existing investment narrative and risk–reward profile.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you need to believe its DNA synthesis and NGS platforms can translate strong revenue growth into a credible path toward profitability while managing dilution and legal risk. The US$300 million follow on offering and raised fiscal 2026 revenue guidance appear to support near term growth initiatives without fundamentally changing the key catalyst, which is progress toward breakeven, or the biggest risk, which remains continued losses and shareholder dilution.

The most relevant announcement here is Twist's upgraded 2026 revenue guidance to US$456 million to US$457 million, alongside Q4 guidance of US$123 million to US$124 million. This guidance frames the offering in the context of a growing top line, which matters because the core near term catalyst is whether Twist can sustain revenue momentum while narrowing losses, rather than simply funding a larger, still unprofitable cost base with new equity capital.

Yet behind the upbeat revenue guidance, investors should be aware of the ongoing class action settlement process and what it could mean for...

Read the full narrative on Twist Bioscience (it's free!)

Twist Bioscience's narrative projects $666.9 million revenue and $113.3 million earnings by 2029.

Uncover how Twist Bioscience's forecasts yield a $92.50 fair value , a 20% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming about 15 percent annual revenue growth and continued losses, so compared with the recent guidance upgrade they paint a far more cautious picture of how quickly Twist can convert sales momentum into sustainable profits.